Crowdonomics
This isn’t InSitu Biologics, Inc.’s most recent raise. Rule 506(b) · Convertible Note · Aug 2026 (Open) is more current.View latest round
InSitu Biologics, Inc.

Reg A+ · Equity · Jun 2018

ClosedReg A+Equity
via the platform · last checked Sep 24, 2026
Raised
$3.9M / $10M max
39% of ceiling
Investors
—
—
Valuation
—
—

Financials disclosed in this offering

No financial statements linked to this round

The issuer's filing for this offering hasn't been parsed into fiscal-year statements yet.

Amendments to this offering

7 amendments
  1. Mar 27, 2019
    Terms not yet extracted from this filing
    Form 1-A POS on EDGAR ↗
  2. Mar 25, 2019
    Terms not yet extracted from this filing
    Form 1-A POS on EDGAR ↗
  3. Jan 4, 2019
    Terms not yet extracted from this filing
    Form 1-A POS on EDGAR ↗
  4. Jul 16, 2018
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗
  5. Jul 11, 2018
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗
  6. Jun 29, 2018
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗
  7. Jun 22, 2018
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. Form 1-A amendments state no reason; those filed before qualification are usually responses to SEC staff review.

Deal terms

Price / share$4.00
Shares offered1,739,132

Offering details

Target—
Max$10,000,009
Min investment—
OpenedJun 5, 2018
Deadline—
ClosedDec 30, 2020
Days active939

Links & provenance

Source: SEC EDGAR
0001477932-18-002887
Last synced Sep 24, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.